Introduction {#j_jccm-2020-0018_s_001}
============

Stress gastritis, and less often stress colitis, occurs in critically ill patients following, amongst other matters, trauma, sepsis, shock, multi-organ failure or those undergoing prolonged surgical treatment \[[@j_jccm-2020-0018_ref_001], [@j_jccm-2020-0018_ref_002], [@j_jccm-2020-0018_ref_003], [@j_jccm-2020-0018_ref_004]\]. Lesions of the gastric mucosa may be focal or diffuse, superficial or potentially resulting in ulceration or gastric haemorrhage, which is associated with significant morbidity and mortality.

The predominant theory of the pathogenesis of gastric mucosal damage caused by stress was, until recently, the destruction of the gastric mucosal barrier due to ischemia, which renders the stomach vulnerable to gastric fluids \[[@j_jccm-2020-0018_ref_001], [@j_jccm-2020-0018_ref_002], [@j_jccm-2020-0018_ref_003]\].

Experimental immobilisation models, involving either exposure to cold \[[@j_jccm-2020-0018_ref_004], [@j_jccm-2020-0018_ref_005], [@j_jccm-2020-0018_ref_006], [@j_jccm-2020-0018_ref_007], [@j_jccm-2020-0018_ref_008]\], or water immersion \[[@j_jccm-2020-0018_ref_009], [@j_jccm-2020-0018_ref_010], [@j_jccm-2020-0018_ref_011], [@j_jccm-2020-0018_ref_012], [@j_jccm-2020-0018_ref_013], [@j_jccm-2020-0018_ref_014], [@j_jccm-2020-0018_ref_015], [@j_jccm-2020-0018_ref_016], [@j_jccm-2020-0018_ref_017], [@j_jccm-2020-0018_ref_018], [@j_jccm-2020-0018_ref_019], [@j_jccm-2020-0018_ref_020], [@j_jccm-2020-0018_ref_021], [@j_jccm-2020-0018_ref_022], [@j_jccm-2020-0018_ref_023], [@j_jccm-2020-0018_ref_024], [@j_jccm-2020-0018_ref_025], [@j_jccm-2020-0018_ref_026], [@j_jccm-2020-0018_ref_027], [@j_jccm-2020-0018_ref_028]\], are well documented as inducing gastric mucosal lesions in rodents. It has been found that each model produces a stimulus that rapidly activates the sympathetic adrenomedullary system, reduces blood flow to the gastric mucosa causing local hypoxia and ischemia, epithelial necrosis and haemorrhagic gastric mucosal corrosion \[[@j_jccm-2020-0018_ref_005], [@j_jccm-2020-0018_ref_006], [@j_jccm-2020-0018_ref_007], [@j_jccm-2020-0018_ref_008], [@j_jccm-2020-0018_ref_009], [@j_jccm-2020-0018_ref_010], [@j_jccm-2020-0018_ref_011], [@j_jccm-2020-0018_ref_012], [@j_jccm-2020-0018_ref_013], [@j_jccm-2020-0018_ref_014], [@j_jccm-2020-0018_ref_015], [@j_jccm-2020-0018_ref_016], [@j_jccm-2020-0018_ref_017], [@j_jccm-2020-0018_ref_018], [@j_jccm-2020-0018_ref_019], [@j_jccm-2020-0018_ref_020], [@j_jccm-2020-0018_ref_021], [@j_jccm-2020-0018_ref_022], [@j_jccm-2020-0018_ref_023], [@j_jccm-2020-0018_ref_024], [@j_jccm-2020-0018_ref_025], [@j_jccm-2020-0018_ref_026], [@j_jccm-2020-0018_ref_027], [@j_jccm-2020-0018_ref_028]\].

Cold restraint stress (CRS) has been found to induce gastric lesions which are associated with decreased or normal levels of acid secretions \[[@j_jccm-2020-0018_ref_027], [@j_jccm-2020-0018_ref_029]\]. Administration of antacids to neutralise secreted acid does not prevent stress ulcer \[[@j_jccm-2020-0018_ref_030]\], suggesting that factors other than gastric acid are involved in ulcer formation. Reactive oxygen species (ROS) such as ·O~2~^-^ and ·OH are now considered to be major causative factors for mucosal lesions through oxidative damage \[[@j_jccm-2020-0018_ref_021], [@j_jccm-2020-0018_ref_022], [@j_jccm-2020-0018_ref_027], [@j_jccm-2020-0018_ref_031], [@j_jccm-2020-0018_ref_032], [@j_jccm-2020-0018_ref_033]\].

Colitis, due to stress, is less frequently found in severely ill patients and has not been clinically investigated because colorectal lesions are often due to drug-damage or disorders of the colonic flora caused by medication.

It has been reported that in experimental rodent models, stress caused by immobilisation contributes to the development of colitis \[[@j_jccm-2020-0018_ref_004]\]. To our knowledge, none of the CRS experimental models has been used to study stress-induced colonic mucosal changes in rodents \[[@j_jccm-2020-0018_ref_004], [@j_jccm-2020-0018_ref_005], [@j_jccm-2020-0018_ref_029]\].

Chios mastic gum (CMG) is a resin naturally produced exclusively in the southern region of the Greek island of Chios, in the Northern Aegean Sea, by prickling the trunk of the shrub Pistacia lentiscus var. Chia. This traditional gum is very popular as a nutritional ingredient, due to its distinct essence, the Eastern Mediterranean and Arab countries. Its beneficial health effects, mainly for gastrointestinal disorders, have been known for more than 2500 years, as documented by Dioscurides and Galen.

Previous studies showed that CMG possesses antiulcer activities \[[@j_jccm-2020-0018_ref_002], [@j_jccm-2020-0018_ref_003]\], while antibacterial, antioxidant, and chemopreventive properties of CMG have also been documented \[[@j_jccm-2020-0018_ref_022], [@j_jccm-2020-0018_ref_034], [@j_jccm-2020-0018_ref_035], [@j_jccm-2020-0018_ref_036], [@j_jccm-2020-0018_ref_037], [@j_jccm-2020-0018_ref_038]\]. Terpenoids are the active compounds of CMG exerting an anti-inflammatory as well as antioxidant effects \[[@j_jccm-2020-0018_ref_036], [@j_jccm-2020-0018_ref_037]\].

Chios mastic gum is effective in the treatment of drug-induced gastroduodenal ulcers and colitis in rats \[[@j_jccm-2020-0018_ref_022], [@j_jccm-2020-0018_ref_036], [@j_jccm-2020-0018_ref_037]\], but without any effect as an in vivo mono-therapy against Helicobacter pylori \[[@j_jccm-2020-0018_ref_038], [@j_jccm-2020-0018_ref_039]\].

Omeprazole has been a standard prevention and treatment medication for peptic ulcer disease since 1989. Indications include gastroesophageal reflux disease, Zollinger-Elisson syndrome, as well as eosinophilic gastritis. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk but has been associated with certain adverse effects and drug interactions \[[@j_jccm-2020-0018_ref_040], [@j_jccm-2020-0018_ref_041]\].

Given that mastic is a natural product of widespread use in many countries, its potential protective effect on the gastric and colonic mucosa may render it a key target for the pharmacological management of critically ill patients. The prevention of stress-induced changes of the gastric and colonic mucosa via nutritional interventions may significantly reduce morbidity and mortality of critically ill patients.

The present study aimed to investigate the protective, antioxidant and anti-inflammatory action of CMG pre-treatment versus Omeprazole, on the CRS effects induced in the rat gastric and colonic mucosa.

The null hypothesis is that CMG has no protective action on the rat peptic mucosa against CRS.

Materials and Methods {#j_jccm-2020-0018_s_002}
=====================

Twenty-one male Wistar rats, aged 12-14 months and weighing 320--380 g, were used in this study \[[@j_jccm-2020-0018_ref_042]\].

The animals were housed in wire cages under standard laboratory conditions. They had been acclimated for two weeks before the experiment in the laboratory. The conditions were 12 h light-dark cycles, 22--25^0^Croom temperature, and 55--58% humidity. The animals were freely fed with a standard laboratory usual pellet diet and water intake.

All experimental procedures in this study were conducted under the Regional State License 1635/1503-2016 and following the European guidelines of Directive 86/609/EEC on the protection and welfare of animals used for experimental and other scientific purposes.

The sample size was determined by power analysis.

The animals were randomly assigned to the following three groups, each of seven animals: Control (C), Omeprazole (O), and CMG (M).

Preparation of administered substances {#j_jccm-2020-0018_s_002_s_001}
--------------------------------------

The substances used were:

1.  Omeprazole suspension (Omeprazole & SyrSpend^®^ SF Alka Convenience Pack 2 mg/mL, Fargon Hellas-Kertus ICSA, Trikala, Hellas)

2.  Chios Mastic natural resin ground in microparticulate form (Chios Mastic Producers Association, Chios, Greece), chemically analysed and suspended in water by shaking.

3.  Control group animals received tap water in place of the active agents.

All substances were prepared immediately before use and administered via an orogastric tube.

The experimental protocol {#j_jccm-2020-0018_s_002_s_002}
-------------------------

Two days before the induced stress, the following was administered to the animals, once a day by orogastric tube.

Group C, additional water 10 mL;\[[@j_jccm-2020-0018_ref_026]\].

Group O, omeprazole 20 mg/kg in water;\[[@j_jccm-2020-0018_ref_021]\].

Group M, Chios mastic gum powder 500 mg in micro-particulate form suspended in water \[[@j_jccm-2020-0018_ref_022],[@j_jccm-2020-0018_ref_023]\]. On the day before the experiment, in order to avoid coprophagy, the animals were placed in wire-bottomed cages and were deprived of food for 24 hours, but had free access to tap water and received the pre-treatment as mentioned above regimen.

On the day of the experiment, the animals were transferred to Bollmann cages, immobilised and kept at a temperature of 4°C for three hours \[[@j_jccm-2020-0018_ref_008]\].

At the end of the experiment, the animals were anesthetized with ketamine 100 mg/kg BW (Ketamin, IFET , Athens, Greece) and xylazine 20 mg/kg BW (Xylamed, Bimeda INC, Oakbrook Terrace, IL, USA). The abdomen of each animal was then opened and 1,5-2,5 mL of blood was obtained from the abdominal aorta for measurement of oxidative stress and inflammation markers by ELISA \[[@j_jccm-2020-0018_ref_012]\].

The entire stomach and ascending colon were then removed for histological examination. All blood and tissue samples were appropriately encoded in order to ensure blind assessment. The animals were euthanized by an intracardiac infusion of 0.6 mg/kg BW pentobarbital sodium BP20% (Dolethal, Vetoquinol Ltd, UK)

Determination of serum antioxidant and anti-inflammatory parameters

The oxidative status was evaluated by determination of the oxidative stress markers peroxidase, total antioxidant capacity in Trolox equivalents (TEAC), and superoxide dismutase (SOD). The anti-inflammatory properties were evaluated by measurement of tumour necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). The concentration of each marker in serum samples was measured by enzyme-linked immunosorbent assay (ELISA).

The *Superoxide Dismutase* Activity (SOD) research-use-only *kit* (Cayman Chemical Company, Ann Arbor, MI, USA) was used to determine serum *superoxide dis-mutase* activity (U/mL).

The assay was performed according to the manufacturer's instructions. Rat serum samples were diluted 1:5 with sample buffer, and the absorbance was measured at 450 nm.

TNF-α and IL-1β serum levels (pg/mL) were determined by ELISA according to the manufacturer's instructions (rat TNF-alpha ELISA kit and rat IL-1 beta ELISA kit, Raybiotech, Norcross, GA, USA). Rat serum samples were diluted 1:2 with assay diluent A. The absorbance was measured at 450 nm.

Antioxidant and peroxide assay kits (Sigma-Aldrich, St. Louis, MO, USA) were employed to determine the total antioxidant capacity and peroxide concentration in serum samples. Both assays were performed according to the manufacturer's instructions. Total antioxidant capacity (mM of Trolox equivalents) was determined in serum samples diluted 1:20 with assay buffer, and the absorbance was measured at 405 nm.

Peroxide concentration (μM H~2~O~2~) was determined in serum samples diluted 1:2 with ultrapure water (Cayman chemical company, Ann Arbor, MI, USA) and the absorbance was measured at 592 nm.

Absorbance measurements were performed using Εxpertplus (ASYS GmBH, Austria) microtiter plate reader.

Pathological assessment of tissues {#j_jccm-2020-0018_s_002_s_003}
----------------------------------

Immediately after removal, the stomachs were inflated by an injecting one mL of 2% formalin then fixed in 2% formalin for ten minutes before being opened along the greater curvature and rinsed with saline to remove the gastric content and clots, before stabilisation in 10% formalin solution. Sections, 5 μm thick, were cut on a microtome (HIRAX M60, Carl Zeiss, Germany) and stained with haematoxylin and eosin (HE).

Gastric mucosal lesions were studied by dissecting microscopy, and the lesion score was calculated.

The damage scores were categorised as follows:

-   A one cm segment of each histological section was assessed for:

    1.  hyperaemia (score: 0--3)

    2.  loss of epithelial cells (EC) (score: 0--3)

    3.  oedema in the upper mucosa (score: 0--3)

    4.  haemorrhagic infiltration (score: 0--3)

    5.  presence of inflammatory cells (IC) (score: 0--3) \[[@j_jccm-2020-0018_ref_019],[@j_jccm-2020-0018_ref_021]\].

-   The average score of gastric mucosal lesions in each group of animals was calculated, and the results were statistically analysed.

-   The ascending colon was immersed and rinsed. Prepared colonic mucosal sections were stabilised with 10% formalin solution; paraffin blocks were formed and stained with HE and Periodic acid--Schiff (*PAS)*. The number of mucin-containing cell-surface cells was quantitated in a region containing ten parallel crypts \[[@j_jccm-2020-0018_ref_004],[@j_jccm-2020-0018_ref_043]\].

-   The results were expressed as the number of mucus-containing cup cells per 100 epithelial cells of the colon \[[@j_jccm-2020-0018_ref_004]\]. Quantitative measurement of colonic mucin was not conducted.

-   The colonic mucosal histological damages identified were:

    1.  hyperaemia (score: 0--3) and

    2.  haemorrhagic infiltration (score: 0--3)

-   The average score of colonic mucosal lesions in each group of animals was calculated, and the results were statistically analysed.

-   The same pathologist blindly screened all encoded preparations.

Statistical analysis {#j_jccm-2020-0018_s_002_s_004}
--------------------

Statistical analysis of the data was performed using SPSS version 19.0 (IBM, Corp.).

The normality of quantitative variables was tested by the Kolmogorov-Smirnov test.

All serum antioxidant and anti-inflammatory parameters were expressed as mean and standard deviation, \[mean(SD)\]..

Differences of these parameters between the three groups were assessed by one-way analysis of variance, (ANOVA).

To show the exact differences between the three different experimental groups, multiple comparisons were performed using the Least Significant Difference (LSD) test, without any adjustment of the significance level.

All indices of the pathological assessment of the tissues, hyperaemia, haemorrhagic infiltration, loss of EC, mucosal oedema and presence of IC for the gastric mucosa, and hyperaemia and haemorrhagic infiltration for the colonic mucosa, were expressed as absolute frequencies and percentages (%) when they were considered as qualitative variables, and as Mean(SD) and Median (min-max) values, when they were considered as quantitative variables.

They were analysed using chi-square test, ANOVA and Kruskal-Wallis test, respectively.

All tests were two-tailed, and the significance level was set at α=0.05.

Results {#j_jccm-2020-0018_s_003}
=======

Chios Mastic Gum Analysis {#j_jccm-2020-0018_s_003_s_001}
-------------------------

The supplied resin was chemically analysed and was found to contain: natural Polymer -- cis-1,4 poly-β-myrcene (25-30 %w/w), mastic oil (2-3%w/w), total mastic extract (70%w/w), acid fraction (38-42%w/w) and neutral fraction (28-32%w/w).

Gastric mucosal response to CRS {#j_jccm-2020-0018_s_003_s_002}
-------------------------------

Following CRS, rats developed gastric mucosal lesions such as hyperaemia, haemorrhagic infiltration, mucosal oedema, loss of EC and infiltration by IC in all three groups ([Figure 1](#j_jccm-2020-0018_fig_001){ref-type="fig"}).

![Gastric mucosa sections. HE x 200. Mucosal changes in: a. Chios mastic group: minimal hyperaemia and oedema, rare inflammatory cells, b. omeprazole group: mild hyperemia and oedema, minor deposits of inflammatory cells c. control: more extensive hyperemia and oedema and deposits of inflammatory cells, moderate hemorrhagic infiltration and pronounced loss of epithelial cells.](jccm-06-100-g001){#j_jccm-2020-0018_fig_001}

The severity of these lesions was affected by the prior administration of either omeprazole or mastic powder.

As shown in [Table 1](#j_jccm-2020-0018_tab_001){ref-type="table"}, measurements of hyperaemia, haemorrhagic infiltration, and mucosal oedema were less pronounced in Groups O and M compared to Group C (chi-square test ; p\<0.05), (ANOVA; p\<0.05), ( Kruskal-Wallis test; p\<0.05), for categorical or continuous variables, respectively ([Figure 2](#j_jccm-2020-0018_fig_002){ref-type="fig"}). The same applied for the loss of EC. (chi-square test; p=0.084.) There were no statistical differences for any of these parameters, between Groups O and M (LSD test and Mann-Whitney U-test; p\>0.05).

###### 

Gastric mucosal lesions in the three groups

                                                        Groups                                   Multiple comparisons                
  --------------------------------------- ------------- ------------- ------------- ------------ ---------------------- ------------ ----------
  Hyperemia                                                                         0.001^a^                                         
  Negative                                0 (0.0)       2 (28.6)      1 (14.3)                                                       
  Low                                     0 (0.0)       5 (71.4)      6 (85.7)                                                       
  Moderate                                6 (85.7)      0 (0.0)       0 (0.0)                                                        
  High                                    1 (14.3)      0 (0.0)       0 (0.0)                                                        
  Mean value (SD)                         2.14 (0.38)   0.71 (0.49)   0.86 (0.38)   \<0.001^b^   \<0.001^c^             \<0.001^c^   0.530^c^
  Median value (min-max)                  2 (2 -- 3)    1 (0 -- 1)    1 (0 -- 1)    \<0.001^d^   0.001^e^               0.001^e^     0.530^e^
                                                                                                                                     
  Hemorrhagic infiltration                                                          0.001                                            
  Negative                                0 (0.0)       7 (100.0)     6 (85.7)                                                       
  Low                                     4 (57.1)      0 (0.0)       1 (14.3)                                                       
  Moderate                                3 (42.9)      0 (0.0)       0 (0.0)                                                        
  High                                    0 (0.0)       0 (0.0)       0 (0.0)                                                        
  Mean value (SD)                         1.43 (0.54)   0.0 (0.0)     0.14 (0.38)   \<0.001      \<0.001                \<0.001      0.489
  Median value (min-max)                  1 (1 -- 2)    0             0 (0 -- 1)    \<0.001      0.001                  0.002        0.317
                                                                                                                                     
  Loss EC                                                                           0.084                                            
  Negative                                0 (0.0)       4 (57.1)      3 (42.9)                                                       
  Low                                     5 (71.4)      3 (42.9)      4 (57.1)                                                       
  Moderate                                2 (28.6)      0 (0.0)       0 (0.0)                                                        
  High                                    0 (0.0)       0 (0.0)       0 (0.0)                                                        
  Mean value (SD)                         1.29 (0.49)   0.43 (0.54)   0.57 (0.54)   0.014        0.006                  0.019        0.613
  edian value (min-max)                   1 (1 -- 2)    0 (0 -- 1)    1 (0 -- 1)    0.026        0.015                  0.030        0.606
                                                                                                                                     
  Oedema                                                                            0.017 ^a^                                        
  Negative                                0 (0.0)       5 (71.4)      4 (57.1)                                                       
  Low                                     7 (100.0)     2 (28.6)      3 (42.9)                                                       
  Moderate                                0 (0.0)       0 (0.0)       0 (0.0)                                                        
  High                                    0 (0.0)       0 (0.0)       0 (0.0)                                                        
  Mean value (SD)                         1.00 (0.0)    0.29 (0.49)   0.43 (0.54)   0.012^b^     0.005^c^               0.020^c^     0.530^c^
  Median value (min-max)                  1             0 (0 -- 1)    0 (0 -- 1)    0.020^d^     0.007^e^               0.023^e^     0.591^e^
                                                                                                                                     
  Infiltration IC                                                                   0.466                                            
  Negative                                3 (42.9)      5 (71.4)      3 (42.9)                                                       
  Low                                     4 (57.1)      2 (28.6)      4 (57.1)                                                       
  Moderate                                0 (0.0)       0 (0.0)       0 (0.0)                                                        
  High                                    0 (0.0)       0 (0.0)       0 (0.0)                                                        
  Mean value (SD)                         0.57 (0.54)   0.29 (0.49)   0.57 (0.54)   0.507        0.317                  1.000        0.317
  Median value (min-max)                  1 (0 -- 1)    0 (0 -- 1)    1 (0 -- 1)    0.483        0.298                  1.000        0.298
  Average histological score, mean (SD)   6.43 (1.13)   1.71 (0.95)   2.57 (1.62)   \<0.001      \<0.001                \<0.001      0.221

a chi-square test; b ANOVA; c LSD test; d Kruskal-Wallis test; e Mann-Whitney Test U-test. C: Control O: Omeprazole M: Mastic Gum.

![Graphic for statistic comparison of gastric mucosal lesions between the three groups.](jccm-06-100-g002){#j_jccm-2020-0018_fig_002}

No statistically significant differences between the three groups were observed regarding the presence of IC. (p\>0.05; chi-square test, ANOVA and Kruskal-Wallis test;). Furthermore, the average total histological score was significantly lower in Group O (p\<0.001;LSD test and Group M (p\<0.001;LSD test) compared to group C. No statistically significant difference was found between Groups O and M (p=0.221; LSD test).

Effects of omeprazole and mastic gum on colonic mucosa {#j_jccm-2020-0018_s_003_s_003}
------------------------------------------------------

In all three groups of animals, cold restraint of rats at 4^0^Cfor three hours produced mucosal changes, as histologically observed in sections of the ascending colon,

Mucosal changes such as hyperaemia and haemorrhagic infiltration were observed in examined sections. The response of the colonic mucosa to the stimulus of stress was calculated by the number of mucin-containing Goblet cells ([Figure 3](#j_jccm-2020-0018_fig_003){ref-type="fig"}) \[[@j_jccm-2020-0018_ref_043]\].

![**Mucin containing mucosal Goblet Cells in histologic sections of the ascending colon, presenting as pink flower petals. Periodic acid--Schiff (***^PAS^***) X 200. a. after pre-treatment with CMG, b. after pre-treatment with Omeprazole and c. in the control group**.](jccm-06-100-g003){#j_jccm-2020-0018_fig_003}

Measurements of hyperaemia and haemorrhagic infiltration of colonic mucosal lesions were less pronounced in Groups O and M compared to Group C. (p=0.001 and p=0.002, respectively; Chi-square test) or (p\<0.001; ANOVA) and (p\<0.001; Kruskal-Wallis test;) ([Table 2](#j_jccm-2020-0018_tab_002){ref-type="table"} and [Figure 4](#j_jccm-2020-0018_fig_004){ref-type="fig"}).

![Graphic of statistic comparison of colonic mucosal lesions in the three groups](jccm-06-100-g004){#j_jccm-2020-0018_fig_004}

###### 

Mucosal lesions observed in the ascending colon in the three groups

                                                        Groups                                     Multiple comparisons                
  -------------------------------------- -------------- -------------- -------------- ------------ ---------------------- ------------ ----------
  Hyperemia                                                                           0.001^a^                                         
  Negative                               0 (0.0)        3 (42.9)       0 (0.0)                                                         
  Low                                    1 (14.3)       4 (57.1)       7 (100.0)                                                       
  Moderate                               3 (42.9)       0 (0.0)        0 (0.0)                                                         
  High                                   3 (42.9)       0 (0.0)        0 (0.0)                                                         
  Mean value (SD)                        2.29 (0.76)    0.57 (0.54)    1.00 (0.0)     \<0.001^b^   \<0.001^c^             \<0.001^c^   0.151^c^
  Median value (min-max)                 2 (1 -- 3)     1 (0 -- 1)     1              0.001^d^     0.003^e^               0.003^e^     0.060^e^
                                                                                                                                       
  Hemorrhagic infiltration                                                            0.002                                            
  Negative                               0 (0.0)        7 (100.0)      5 (71.4)                                                        
  Low                                    3 (42.9)       0 (0.0)        2 (28.6)                                                        
  Moderate                               4 (57.1)       0 (0.0)        0 (0.0)                                                         
  High                                   0 (0.0)        0 (0.0)        0 (0.0)                                                         
  Mean value (SD)                        1.57 (0.54)    0.0 (0.0)      0.29 (0.49)    \<0.001      \<0.001                \<0.001      0.217
  Median value (min-max)                 2 (1 -- 2)     0              0 (0 -- 1)     \<0.001      0.001                  0.004        0.141
  Average Histological Score,mean (SD)   3.86 (1.22)    0.57 (0.54)    1.29 (0.49)    \<0.001      \<0.001                \<0.001      0.119
  Number of Goblet cells                 50.54 (3.56)   52.71 (2.84)   52.51 (2.83)   0.370        0.206                  0.249        0.905

chi-square test; ^b^ ANOVA; ^c^ LSD test; ^d^ Kruskal-Wallis test; ^e^ Mann-Whitney Test U-test. C: Control O: Omeprazole M: Mastic Gum.

Both hyperaemia and haemorrhagic infiltration were similar between Groups O and M (p\>0.05; LSD test and Mann-Whitney U-test). Furthermore, the average total histological score was significantly lower in Group O ( p\<0.001;LSD test) and Group M (p\<0.001;LSD test) compared to Group C. No statistically significant difference was found between Groups O and M (p=0.119; LSD test). No statistically significant differences between the three groups were observed concerning the number of colonic Goblet cells (p=0.370;ANOVA) [Table 2](#j_jccm-2020-0018_tab_002){ref-type="table"}.

Antioxidative and anti-inflammatory properties of Omeprazole and mastic resin {#j_jccm-2020-0018_s_003_s_004}
-----------------------------------------------------------------------------

[Table 3](#j_jccm-2020-0018_tab_003){ref-type="table"} contains the results for the comparison of the anti-inflammatory and the oxidative stress markers between the three groups, both altogether and in pairs ([Figure 5](#j_jccm-2020-0018_fig_005){ref-type="fig"}).

![Graphics of statistic comparison of antioxidant and anti- inflammatory markers between the three groups](jccm-06-100-g005){#j_jccm-2020-0018_fig_005}

###### 

Serum antioxidant and anti-inflammatory markers in the three groups

                                                Groups                                    Multiple comparisons^b^             
  ----------------------------- --------------- --------------- --------------- --------- ------------------------- --------- -------
  μΜ Peroxidase/mg of protein   0.151 (0.039)   0.144 (0.027)   0.110 (0.016)   0.039     0.666                     0.018     0.043
  mM TEAC/mg protein            0.024 (0.006)   0.028 (0.004)   0.031 (0.009)   0.277     0.386                     0.114     0.450
  SOD U/mg protein              0.156 (0.012)   0.104 (0.016)   0.087 (0.016)   \<0.001   \<0.001                   \<0.001   0.047
  pg TNFa/mg protein            0.999 (0.437)   1.202 (0.396)   0.653 (0.264)   0.040     0.322                     0.100     0.013
  pg IL1β/mg of protein         4.399 (1.450)   2.426 (0.762)   1.587 (0.291)   \<0.001   0.001                     \<0.001   0.120

comparison between groups (one-way ANOVA); ^b^ pair-wise comparisons between groups (LSD test). C: Control O: Omeprazole M: Mastic Gum. TEAC: Trolox Equivalent antioxidant capacity, SOD: Superoxide dismutase.

Statistically significant differences of peroxidase levels were observed between the three groups (p=0.039; ANOVA).

Post-hoc analysis revealed that 27.2% lower peroxidase levels were observed in Group M compared to Group C (p=0.018; LSD test) and by 23.6% in Group O (p=0.043;LSD test).

Peroxidase levels were not significantly different in groups C and O (p=0.666;LSD test).

No statistically significant difference of TEAC levels was observed between the three groups (p=0.277;ANOVA)

Analysis of variance revealed statistically significant differences in SOD levels between the three groups (p\<0.001). Post-hoc analysis using LSD test revealed that, compared to group C, SOD levels were by 33.3% lower in Group O (p\<0.001) and 44.2%, lower in group M (p\<0.001). Moreover, SOD levels were significantly lower in Group M compared to Group O, by 16.3%, (p=0.047).

Regarding the anti-inflammatory properties, analysis of variance showed statistically significant differences in TNF-α and IL-1β levels between the three groups ([Table 3](#j_jccm-2020-0018_tab_003){ref-type="table"}).

TNF-α levels were 34.6% lower in Group M compared to Group C (p=0.100) and significantly lower, by 45.7%, compared to Group O (p=0.013).

Compared to Group C, lower IL-1β levels by 44.9%, were observed in Group O (p=0.001) and by 63.9%, in Group M (p\<0.001).

Moreover, there was a 34.6% lower level of IL-1β in Group M compared to Group O (p=0.120), but this difference did not reach the statistical significance.

Discussion {#j_jccm-2020-0018_s_004}
==========

Numerous studies have documented that CRS induces gastric mucosal lesions as a result of oxidative damage caused by the significant generation of \_ OH \[[@j_jccm-2020-0018_ref_013], [@j_jccm-2020-0018_ref_022], [@j_jccm-2020-0018_ref_028], [@j_jccm-2020-0018_ref_029], [@j_jccm-2020-0018_ref_030]\].

In the present study, CMG was tested vs Omeprazole as a protection of the gastric and colonic mucosa against CRS induced by a mild severity protocol. The antioxidant and anti-inflammatory effects of the two agents were also evaluated.

Omeprazole is a selective and irreversible proton pump inhibitor, which suppresses stomach acid secretion by specific inhibition of the H^+^/K^+^-ATPase system found at the secretory surface of gastric parietal cells \[[@j_jccm-2020-0018_ref_040], [@j_jccm-2020-0018_ref_041]\]. Biswas et al. (2003) have demonstrated that Omeprazole not only acts by decreasing gastric acid secretion \[[@j_jccm-2020-0018_ref_044]\].

It blocks the stress-induced increased generation of ·OH and associated lipid peroxidation and protein oxidation, indicating that its antioxidant role plays a major part in preventing oxidative damage. Omeprazole also prevents stress-induced DNA fragmentation caused by ·OH in vitro \[[@j_jccm-2020-0018_ref_044]\]. However, serious side effects associated with Omeprazole may include *Clostridium difficile* colitis, an increased risk of pneumonia or bone fractures. Moreover, acting as an inhibitor of the enzymes CYP2C19 and CYP3A4, Omeprazole may alter the absorption and plasma levels of anticoagulants, antidepressants, analgesics and some antibiotics \[[@j_jccm-2020-0018_ref_040], [@j_jccm-2020-0018_ref_041]\].

Consistent with previous experimental findings, histological changes of the gastric mucosa were observed in the herein study, such as hyperaemia, haemorrhagic infiltration, loss of EC, mucosal oedema and presence of IC in all three groups of animals, while true ulcers were not detected. The beneficial preventive effect of either Omeprazole or mastic gum compared to the control group was more pronounced for hyperaemia, haemorrhagic infiltration, loss of EC and oedema and almost non-existent for the presence of IC. However, no statistically significant effect was evident when comparing Omeprazole vs mastic gum for any of the five histological parameters.

These results suggest that CMG acts as efficiently as Omeprazole in the prevention of hyperaemia and haemorrhagic infiltration, oedema and loss of EC in the gastric mucosa of rats caused by CRS.

Hyperaemia and haemorrhagic infiltration of the colonic mucosa were less pronounced after omeprazole or mastic gum administration compared to the control group, but not significantly different between the two agents. Based on the results, CMG prevents hyperaemia and haemorrhagic infiltration of the colonic mucosa caused by CRS.

Colonic mucin- containing cup cells that were quantitatively evaluated synthesise and secrete mucins, high molecular weight glycoproteins, which form a protective layer throughout the gastrointestinal (GI) tract. This layer acts as an effective barrier as shown by changes in mucins in inflammatory conditions of the GI tract, by the altered Goblet cell response in germ-free animals, and by the enhanced mucus secretion seen in response to infections \[[@j_jccm-2020-0018_ref_004], [@j_jccm-2020-0018_ref_043]\]. Quantitative and qualitative evaluation of the mucin was not evaluated in the present study.

Triantafyllou et al. (2011) have demonstrated that the anti-inflammatory activity of CMG is associated with its antioxidant activity \[[@j_jccm-2020-0018_ref_037]\]. Pro-inflammatory cytokines stimulate superoxide production by NADPH oxidases, thus providing feed-forward activation of inflammatory pathways. This superoxide production is inhibited by mastic gum. It is suggested by recent studies that CMG acts as a peroxisome proliferator-activated receptor (PPAR) modulator \[[@j_jccm-2020-0018_ref_045]\]. PPARs are nuclear receptors that control cellular functions via transcription at the level of gene expression implicated in the pathways of metabolic syndrome, inflammation, atheromatosis, and cancer \[[@j_jccm-2020-0018_ref_036], [@j_jccm-2020-0018_ref_045]\].

In the present study, it was evident that the mastic gum affected the antioxidant enzymes peroxidase and SOD.

Administration of mastic gum significantly decreased the activity of both enzymes compared to the levels observed by the administration of Omeprazole. SOD, but not peroxidase, was also significantly reduced for Omeprazole compared to the control group.

Regarding the anti-inflammatory properties of CMG, the inhibition of pro-inflammatory cytokines such as prostaglandin E2 (PGE2) and nitric oxide (NO) is mainly attributed to the inhibition of iNOS and COX-2 protein expression by activated macrophages rather than the scavenging of NO \[[@j_jccm-2020-0018_ref_046]\].

Also, in studies on experimental colitis, CGM administration resulted in a significant reduction of inflammatory markers as TNF-a, IL-6, and ICAM-1 and downregulated NF-jB p65 \[[@j_jccm-2020-0018_ref_037], [@j_jccm-2020-0018_ref_038]\]. Papalois et al. \[[@j_jccm-2020-0018_ref_036]\] have demonstrated that Chios mastic as a whole rather than its acidic, neutral components or oleanolic acid, exerts an anti-inflammatory effect on the colonic mucosa in trinitrobenzene sulfonic acid (TNBS)-induced colitic in rats via NF-jB regulation.

Mastic gum, in the present study, demonstrated lower values for the pro-inflammatory cytokine TNF-α compared to Omeprazole and for IL-1β compared to the control group.

Conclusions {#j_jccm-2020-0018_s_005}
===========

Peptic mucosal damage induced by acute stress is a serious cause of morbidity and mortality in critically ill patients. In this study, a mild CRS protocol induced peptic mucosal alterations, which were decreased in animals pre-treated with either CMG or Omeprazole. Furthermore, CMG appeared to significantly reduce hyperaemia, haemorrhagic infiltration, oedema and loss of epithelial cells to the gastric mucosa as well as hyperaemia and haemorrhagic infiltration to the colonic mucosa. At the same time, its antioxidative and anti-inflammatory properties, tested by various markers, were found comparable to those of Omeprazole.

It is concluded that Chios mastic resin is effective against CRS- induced peptic mucosal damage in rats.

The study showed promising results of the use of Chios mastic gum as a nutritional supplement and its incorporation in therapeutic research protocols in clinical practice.
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